Guggenheim Reiterates Buy on AbbVie, Maintains $249 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.2%

Neg 0% Neu 88.2% Pos 0%

Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $249 price target.

Comments

No comments yet. Be the first!